Understanding the current landscape Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) present a range of clinical challenges, from symptom control to tumor progression. Somatostatin analogs (SSAs) such as octreotide LAR and lanreotide are first-line therapies for many patients with metastatic or unresectable GEP-NETs. They help control hormone-related symptoms and often stabilize tumor growth. As trial data accumulate, physicians…